N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulfasalazine in the treatment of inflammatory bowel disease

Canadian Journal of Gastroenterology

Volumn 21, Issue 3, 2007, Pages 155-158

  Chen, Min ^a   Xia, Bing ^a,b   Chen, Bixiao ^a   Guo, Qiusha ^a   Li, Jin ^a   Ye, Mei ^b   Hu, Zhengguo ^b  

^a WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

Adverse effects; Genetic polymorphism; Inflammatory bowel disease; N acetyltransferase 2; Sulfasalazine

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; SALAZOSULFAPYRIDINE; ACYLTRANSFERASE; NAT2 PROTEIN, HUMAN; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHINESE; CONTROLLED STUDY; CROHN DISEASE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; ENTERITIS; FEMALE; GASTROINTESTINAL DISEASE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL SIGNIFICANCE; ULCERATIVE COLITIS; WILD TYPE; ACETYLATION; ALLELE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED;

ACETYLATION; ACETYLTRANSFERASES; ADOLESCENT; ADULT; AGED; ALLELES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYLAMINE N-ACETYLTRANSFERASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SULFASALAZINE;

EID: 34249946316     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2007/976804     Document Type: Article

References (21)

1. Hein DW, Doll MA, Fretland AJ, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms, Cancer Epidemiol Biomarkers Prev 2000;9:29-42.
2. Hein DW. Molecular genetics and function of NAT1 and NAT2: Role in aromatic amine metabolism and carcinogenesis. Mutat Res 2002;506-507:65-77.
3. Hickman D, Pope J, Patil SD, et al. Expression of arylamine N-acetyltransferase in human intestine. Gut 1998;42:402-9.
4. Gunnarsson I, Kanerud L, Pettersson E, Lundberg I, Lindblad S, Ringertz B. Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. Br J Rheumatol 1997;36:1089-94.
5. Pawlik A, Ostanek L, Brzosko I, Gawroska-Szklarz B, Brzosko M, Dabrowska-Zamojcin E. Increased genotype frequency of N-aceryltransferase 2 slow acetylation in patients with rheumatoid arthritis. Clin Pharmacol Ther 2002;72:319-25.
6. Najim RA, Sharquie KE, Al-Janabi MH. Acetylator phenotype in Behcet's disease. Adv Exp Med Biol 2003;528:131-8.
7. Tanaka E, Taniguchi A, Urano W, et al. Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol 2002;29:2492-9.
8. Sanderson JD. IBD: Diagnosis and control Practitioner 1997;241:120-2,127-8,130.
9. Zielinska E, Niewiarowski W, Bodalski J, et al. Genotyping of the arylamine N-acetyltransferase polymorphism in the prediction of idiosyncratic reactions to trimethoprim-sulfamethoxazole in infants. Pharm World Sci 1998;20:123-30.
10. Yokogawa K, Nakaharu T, Ishizaki J, et al. Kinetic phenotypic diagnosis of N-acetylation polymorphism in patients based on ratio of urinary metabolites of salicylazosulfapyridine. Int J Pharm 2001;229:183-91.
11. Edwards IR, Aronson JK. Adverse drug reactions: Definitions, diagnosis, and management. Lancet 2000;356:1255-9.
12. Deguchi T, Mashimo M, Suzuki T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J Biol Chem 1990;265:12757-60.
13. Tanigawara Y, Kita T, Aoyama N, et al. N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events. Biol Pharm Bull 2002;25:1058-62.
14. Kumagai S, Komada F, Kita T, et al. N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis. Pharm Res 2004;21:324-9.
15. Gao JP, Huang YD, Lin JA, Zhu QC, Liang JP. [Relationship between genetic polymorphisms of N-acetyltransferase and susceptibility to hepatocellular carcinoma]. Zhonghua Gan Zang Bing Za Zhi 2003;11:20-2.
16. von Schmiedeberg S, Goebel C, Gleichmann E, Uetrecht J. Neutrophils and drug metabolism. Science 1995;268:585-6. (Lett)
17. Ricart E, Taylor WR, Loftus EV, et al. N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis. Am J Gastroenterol 2002;97:1763-8.
18. Cascorbi I, Brockmoller J, Mrozikiewicz PM, Muller A, Roots I. Arylamine N-aceryltransferase activity in man. Drug Metab Rev 1999;31:489-502.
19. Das KM, Eastwood MA, McManus JP, Sircus W. The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients. Gut 1973;14:631-41.
20. Lin HJ, Han CY, Lin BK, Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics; 1994;4:125-34.
21. Bell DA, Taylor JA, Butler MA, et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993;14:1689-92.